- $2.65bn
- $3.04bn
- $605.49m
Transmedics Group Inc reports results for the quarter ended June 30 - Earnings Summary
TransMedics Q2 net income declines on R&D and infrastructure expenses
Brief: Transmedics Group Q2 EPS USD 0.41
TransMedics Q1 revenue edges past estimates
Brief: Transmedics Group Q1 EPS USD 0.2
Brief: Transmedics Group Announces Intent To Create The First Dedicated European Transplant Logistics Network
U.S. RESEARCH ROUNDUP-East West Bancorp, Reliance, S&P Global
Brief: Transmedics Provides Information On Impact Of Release Of Valuation Allowance On Deferred Tax Assets On Previously Reported Quarterly Results
TransMedics Q4 revenue rises 32%, beats expectations
Brief: Transmedics Receives Full And Unconditional FDA Ide Approval For Next-Generation Ocs Heart Enhance Trial
Brief: Transmedics Announces New Global Headquarters And Expansion At Assembly Innovation Park In Somerville, Massachusetts
U.S. STOCKS ON THE MOVE-Fiserv, CMS Energy, Moderna
U.S. STOCKS ON THE MOVE-Wolfspeed, Carvana, Metsera
TransMedics drops as Q3 revenue misses analyst estimates
Medical device maker TransMedics Q3 revenue misses estimates
Brief: Transmedics Group Says Unit Buys Fixed-Wing Aircraft For $14.5 Mln From Teaghlach Aviation
U.S. RESEARCH ROUNDUP-Abbvie, Kroger, Workday
Brief: Transmedics Receives FDA Ide Approval To Initiate Next-Generation Ocs Heart Trial
Transmedics Group Inc reports results for the quarter ended June 30 - Earnings Summary